Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59


Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial.

Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, Oltersdorf T, Okuda T, Feldman HH; Alzheimer’s Disease Cooperative Study TCAD Study Group.

JAMA Neurol. 2019 Jul 8. doi: 10.1001/jamaneurol.2019.1868. [Epub ahead of print]


Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.

Huisa BN, Thomas RG, Jin S, Oltersdorf T, Taylor C, Feldman HH.

J Alzheimers Dis. 2019;67(2):707-713. doi: 10.3233/JAD-180684.


Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study.

Gauthier S, Rountree S, Finn B, LaPlante B, Weber E, Oltersdorf T.

J Alzheimers Dis. 2015;48(2):473-81. doi: 10.3233/JAD-150414.


Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.

Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA.

Hepatology. 2007 Aug;46(2):324-9.


Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC, Nimmer PM, Oltersdorf T, Park CM, Petros AM, Shoemaker AR, Song X, Wang X, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, Elmore SW.

J Med Chem. 2007 Feb 22;50(4):641-62. Epub 2007 Jan 26.


Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury.

Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, Burgart L, Garrity-Park M, van Vilsteren FG, Oliver LK, Rosen CB, Gores GJ.

Am J Transplant. 2007 Jan;7(1):218-25.


A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, Deckwirth T, Frost DJ, Jarvis K, Joseph MK, Marsh K, McClellan W, Nellans H, Ng S, Nimmer P, O'Connor JM, Oltersdorf T, Qing W, Shen W, Stavropoulos J, Tahir SK, Wang B, Warner R, Zhang H, Fesik SW, Rosenberg SH, Elmore SW.

Cancer Res. 2006 Sep 1;66(17):8731-9.


Quantitative analysis of anti-apoptotic function of Akt in Akt1 and Akt2 double knock-out mouse embryonic fibroblast cells under normal and stressed conditions.

Liu X, Shi Y, Birnbaum MJ, Ye K, De Jong R, Oltersdorf T, Giranda VL, Luo Y.

J Biol Chem. 2006 Oct 20;281(42):31380-8. Epub 2006 Aug 21.


Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.

Woods KW, Fischer JP, Claiborne A, Li T, Thomas SA, Zhu GD, Diebold RB, Liu X, Shi Y, Klinghofer V, Han EK, Guan R, Magnone SR, Johnson EF, Bouska JJ, Olson AM, de Jong R, Oltersdorf T, Luo Y, Rosenberg SH, Giranda VL, Li Q.

Bioorg Med Chem. 2006 Oct 15;14(20):6832-46. Epub 2006 Jul 14.


Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.

Zhu GD, Gandhi VB, Gong J, Luo Y, Liu X, Shi Y, Guan R, Magnone SR, Klinghofer V, Johnson EF, Bouska J, Shoemaker A, Oleksijew A, Jarvis K, Park C, Jong RD, Oltersdorf T, Li Q, Rosenberg SH, Giranda VL.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3424-9. Epub 2006 Apr 27.


Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.

Zhu GD, Gong J, Claiborne A, Woods KW, Gandhi VB, Thomas S, Luo Y, Liu X, Shi Y, Guan R, Magnone SR, Klinghofer V, Johnson EF, Bouska J, Shoemaker A, Oleksijew A, Stoll VS, De Jong R, Oltersdorf T, Li Q, Rosenberg SH, Giranda VL.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3150-5. Epub 2006 Apr 5.


Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

Wendt MD, Shen W, Kunzer A, McClellan WJ, Bruncko M, Oost TK, Ding H, Joseph MK, Zhang H, Nimmer PM, Ng SC, Shoemaker AR, Petros AM, Oleksijew A, Marsh K, Bauch J, Oltersdorf T, Belli BA, Martineau D, Fesik SW, Rosenberg SH, Elmore SW.

J Med Chem. 2006 Feb 9;49(3):1165-81.


Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.

Li Q, Woods KW, Thomas S, Zhu GD, Packard G, Fisher J, Li T, Gong J, Dinges J, Song X, Abrams J, Luo Y, Johnson EF, Shi Y, Liu X, Klinghofer V, Des Jong R, Oltersdorf T, Stoll VS, Jakob CG, Rosenberg SH, Giranda VL.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):2000-7. Epub 2006 Jan 18.


Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.

Li Q, Li T, Zhu GD, Gong J, Claibone A, Dalton C, Luo Y, Johnson EF, Shi Y, Liu X, Klinghofer V, Bauch JL, Marsh KC, Bouska JJ, Arries S, De Jong R, Oltersdorf T, Stoll VS, Jakob CG, Rosenberg SH, Giranda VL.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1679-85. Epub 2006 Jan 5.


Cytochrome c dissociation and release from mitochondria by truncated Bid and ceramide.

Yuan H, Williams SD, Adachi S, Oltersdorf T, Gottlieb RA.

Mitochondrion. 2003 Mar;2(4):237-44.


Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.

Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han EK, Li T, Stoll VS, Powlas JA, Oleksijew A, Mitten MJ, Shi Y, Guan R, McGonigal TP, Klinghofer V, Johnson EF, Leverson JD, Bouska JJ, Mamo M, Smith RA, Gramling-Evans EE, Zinker BA, Mika AK, Nguyen PT, Oltersdorf T, Rosenberg SH, Li Q, Giranda VL.

Mol Cancer Ther. 2005 Jun;4(6):977-86.


An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH.

Nature. 2005 Jun 2;435(7042):677-81. Epub 2005 May 15.


Role for Akt3/protein kinase Bgamma in attainment of normal brain size.

Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T, Efstratiadis A, Birnbaum MJ.

Mol Cell Biol. 2005 Mar;25(5):1869-78.


Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth.

Liu X, Powlas J, Shi Y, Oleksijew AX, Shoemaker AR, De Jong R, Oltersdorf T, Giranda VL, Luo Y.

Anticancer Res. 2004 Sep-Oct;24(5A):2697-704.


Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.

Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL, Ding H, Elmore SW, Meadows RP, Olejniczak ET, Oleksijew A, Oltersdorf T, Rosenberg SH, Shoemaker AR, Tomaselli KJ, Zou H, Fesik SW.

J Med Chem. 2004 Aug 26;47(18):4417-26.


Mutational analysis of the interacting cell death regulators CED-9 and CED-4.

Ottilie S, Wang Y, Banks S, Chang J, Vigna NJ, Weeks S, Armstrong RC, Fritz LC, Oltersdorf T.

Cell Death Differ. 1997 Oct;4(7):526-33.


Abrogation of disease development in plants expressing animal antiapoptotic genes.

Dickman MB, Park YK, Oltersdorf T, Li W, Clemente T, French R.

Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6957-62. Epub 2001 May 29. Erratum in: Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11816.


Solution structure of the antiapoptotic protein bcl-2.

Petros AM, Medek A, Nettesheim DG, Kim DH, Yoon HS, Swift K, Matayoshi ED, Oltersdorf T, Fesik SW.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3012-7. Epub 2001 Feb 27.


Monitoring interactions of Bcl-2 family proteins in 96-well plate assays.

Diaz JL, Oltersdorf T, Fritz LC.

Methods Enzymol. 2000;322:255-66. No abstract available.


Neuron-specific transgene expression of Bcl-XL but not Bcl-2 genes reduced lesion size after permanent middle cerebral artery occlusion in mice.

Wiessner C, Allegrini PR, Rupalla K, Sauer D, Oltersdorf T, McGregor AL, Bischoff S, Böttiger BW, van der Putten H.

Neurosci Lett. 1999 Jun 25;268(3):119-22.


IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.

Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC.

Cancer Res. 1998 Dec 1;58(23):5315-20.


Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins.

Ottilie S, Diaz JL, Horne W, Chang J, Wang Y, Wilson G, Chang S, Weeks S, Fritz LC, Oltersdorf T.

J Biol Chem. 1997 Dec 5;272(49):30866-72.


Structural and functional complementation of an inactive Bcl-2 mutant by Bax truncation.

Ottilie S, Diaz JL, Chang J, Wilson G, Tuffo KM, Weeks S, McConnell M, Wang Y, Oltersdorf T, Fritz LC.

J Biol Chem. 1997 Jul 4;272(27):16955-61.


A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members.

Diaz JL, Oltersdorf T, Horne W, McConnell M, Wilson G, Weeks S, Garcia T, Fritz LC.

J Biol Chem. 1997 Apr 25;272(17):11350-5.


Bax- and Bak-induced cell death in the fission yeast Schizosaccharomyces pombe.

Jürgensmeier JM, Krajewski S, Armstrong RC, Wilson GM, Oltersdorf T, Fritz LC, Reed JC, Ottilie S.

Mol Biol Cell. 1997 Feb;8(2):325-39.


Beta-secretase processing of the beta-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes.

Zhao J, Paganini L, Mucke L, Gordon M, Refolo L, Carman M, Sinha S, Oltersdorf T, Lieberburg I, McConlogue L.

J Biol Chem. 1996 Dec 6;271(49):31407-11.


Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL 1R-rp2).

Lovenberg TW, Crowe PD, Liu C, Chalmers DT, Liu XJ, Liaw C, Clevenger W, Oltersdorf T, De Souza EB, Maki RA.

J Neuroimmunol. 1996 Nov;70(2):113-22.


Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid.

Liaw CW, Lovenberg TW, Barry G, Oltersdorf T, Grigoriadis DE, de Souza EB.

Endocrinology. 1996 Jan;137(1):72-7.


Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain.

Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, Oltersdorf T.

Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):836-40. Erratum in: Proc Natl Acad Sci U S A 1995 Jun 6;92(12):5759.


Expression of potentially amyloidogenic derivatives of the Alzheimer amyloid precursor protein in cultured 293 cells.

Johnstone EM, Oltersdorf T, Bales KR, Chaney MO, Santerre RF, Little SP.

Neurosci Lett. 1994 Oct 24;180(2):151-4.


Identification of secreted beta-amyloid precursor protein binding sites on intact human fibroblasts.

Johnson-Wood KL, Henriksson T, Seubert P, Oltersdorf T, Lieberburg I, Schenk DB.

Biochem Biophys Res Commun. 1994 May 16;200(3):1685-92.


Colorimetric assay for rapid screening of corticotropin releasing factor receptor ligands.

Liaw CW, Grigoriadis DE, De Souza EB, Oltersdorf T.

J Mol Neurosci. 1994 Summer;5(2):83-92.


Regulated cleavage of Alzheimer beta-amyloid precursor protein in the absence of the cytoplasmic tail.

da Cruz e Silva OA, Iverfeldt K, Oltersdorf T, Sinha S, Lieberburg I, Ramabhadran TV, Suzuki T, Sisodia SS, Gandy S, Greengard P.

Neuroscience. 1993 Dec;57(4):873-7.


Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules.

Haass C, Hung AY, Schlossmacher MG, Oltersdorf T, Teplow DB, Selkoe DJ.

Ann N Y Acad Sci. 1993 Sep 24;695:109-16.


Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide.

Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ, et al.

Nature. 1993 Jan 21;361(6409):260-3.


Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production.

Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ.

Nature. 1992 Dec 17;360(6405):672-4.


Cleavage of amyloid beta peptide during constitutive processing of its precursor.

Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, McClure D, Ward PJ.

Science. 1990 Jun 1;248(4959):1122-4.


The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway.

Oltersdorf T, Ward PJ, Henriksson T, Beattie EC, Neve R, Lieberburg I, Fritz LC.

J Biol Chem. 1990 Mar 15;265(8):4492-7.


Analysis of the beta-amyloid protein precursor of Alzheimer's disease: mRNAs and protein products.

Palmert MR, Podlisny MB, Golde TE, Cohen ML, Kovacs DM, Tanzi RE, Gusella JF, Whitehouse PJ, Witker DS, Oltersdorf T, et al.

Adv Neurol. 1990;51:181-4. Review. No abstract available.


The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II.

Oltersdorf T, Fritz LC, Schenk DB, Lieberburg I, Johnson-Wood KL, Beattie EC, Ward PJ, Blacher RW, Dovey HF, Sinha S.

Nature. 1989 Sep 14;341(6238):144-7.


Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts.

Saitoh T, Sundsmo M, Roch JM, Kimura N, Cole G, Schubert D, Oltersdorf T, Schenk DB.

Cell. 1989 Aug 25;58(4):615-22.


The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid.

Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG.

Proc Natl Acad Sci U S A. 1989 Aug;86(16):6338-42.


Amyloid beta protein precursor is a mitogen.

Schubert D, Cole G, Saitoh T, Oltersdorf T.

Biochem Biophys Res Commun. 1989 Jul 14;162(1):83-8.


The beta amyloid protein precursor: mRNAs, membrane-associated forms, and soluble derivatives.

Palmert MR, Podlisny MB, Golde TE, Cohen ML, Kovacs DM, Tanzi RE, Gusella JF, Whitehouse PJ, Witker DS, Oltersdorf T, et al.

Prog Clin Biol Res. 1989;317:971-84. Review.


Supplemental Content

Loading ...
Support Center